PARP inhibition in BRCA-mutated breast and ovarian cancers
- 1 July 2010
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 376 (9737) , 211-213
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialThe Lancet, 2010
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialThe Lancet, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast CancerJournal of Clinical Oncology, 2006
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 2005
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus TopotecanJournal of Clinical Oncology, 2001
- Breast Cancer Susceptibility Genes: BRCA1 and BRCA2Medicine, 1998